Learn More
Protective immunity against influenza virus infection is mediated by neutralizing antibodies, but the precise role of T cells in human influenza immunity is uncertain. We conducted influenza infection studies in healthy volunteers with no detectable antibodies to the challenge viruses H3N2 or H1N1. We mapped T cell responses to influenza before and during(More)
The immunolglobulin-like transcript (ILT) family of proteins are surface receptors expressed by antigen-presenting cells capable of modulating host cell functions through intracellular signaling. Here we discuss the recent studies regarding the role of dendritic cell (DC)-expressed ILT receptors in suppressor T (Ts) cells induced DC tolerization.(More)
There is great interest in the development of Ab-inducing subunit vaccines targeting infections, including HIV, malaria, and Ebola. We previously reported that adenovirus vectored vaccines are potent in priming Ab responses, but uncertainty remains regarding the optimal approach for induction of humoral immune responses. In this study, using OVA as a model(More)
Induction of broadly neutralizing antibodies (bnAbs) is a goal of HIV-1 vaccine development. bnAbs occur in some HIV-1-infected individuals and frequently have characteristics of autoantibodies. We have studied cohorts of HIV-1-infected individuals who made bnAbs and compared them with those who did not do so, and determined immune traits associated with(More)
Control of virus replication in HIV-1 infection is critical to delaying disease progression. While cellular immune responses are a key determinant of control, relatively little is known about the contribution of the infecting virus to this process. To gain insight into this interplay between virus and host in viral control, we conducted a detailed analysis(More)
A randomized clinical trial was conducted to assess whether the immunogenicity of seasonal and pandemic (H1N1/09) influenza vaccines is affected by the order of vaccine administration. 151 healthy adult volunteers were randomized into three groups. All groups received one dose (15 μg haemagglutinin) each of a pandemic H1N1 vaccine and a seasonal trivalent(More)
BACKGROUND  Antibodies play a major role in the protection against influenza virus in human. However, the antibody level is usually short-lived and the cellular mechanisms underlying influenza virus-specific antibody response to acute infection remain unclear. METHODS  We studied the kinetics and magnitude of influenza virus-specific B-cell and serum(More)
permits non-commercial use, distribution and reproduction of the article, provided the original work is appropriately acknowledged with correct citation details. Since the first appearance of the pandemic (H1N1) 2009 virus many efforts have been made to monitor the changes of the virus at molecular level with the aim to early detect mutations which could(More)
A full list of authors and affiliations appears at the end of the paper. a an academic bioentrepreneur, you will face many challenges. At the very least, you must identify a novel and valuable life science opportunity, create a viable business model, build a team with technical and business acumen, manage resources and orchestrate partnerships, communicate(More)
  • 1